Tolerability Assessment of Tyrosine Kinase Inhibitors in Patients With Solid Tumor Malignancies and Hypoalbuminemia
Annals of Pharmacotherapy · 2025
DOI: 10.1177/10600280241284923 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Pharmacotherapy, 2025. Verfasst von Sarvnaz Sadrameli und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, University of Chicago Medicine, Chicago, IL, USA. Hauptthemen laut MEDLINE: Hypoalbuminemia, Protein Kinase Inhibitors, Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 24 Literaturangaben.
Abstract (Originalsprache)
Background
Hypoalbuminemia is common in patients with advanced solid tumor malignancies. However, despite the increased use of highly protein-bound tyrosine kinase inhibitors (TKIs) in cancer treatments, the tolerability of these agents in patients with hypoalbuminemia is not fully known.
Objective
Our aim is to assess whether patients on oral TKIs with hypoalbuminemia are at higher risk for experiencing medication-related adverse events, therefore requiring careful considerations.
Methods
This is a single-center, retrospective study including patients ≥18 years of age with a solid tumor malignancy who had taken at least one dose of oral TKIs with a protein binding of ≥90% between June 1, 2016, and June 1, 2021. The primary outcome was to compare time to TKI discontinuation due to adverse events between patients with and without hypoalbuminemia. Key secondary outcomes include TKI discontinuation and dose reduction rates, time to TKI dose reduction, and severity of adverse events.
Results
Out of 282 included patients, 134 (48%) patients had hypoalbuminemia and 148 (52%) had normal albumin levels. Compared with patients without hypoalbuminemia, patients with hypoalbuminemia had shorter median time on treatment at 2.8 months (95% CI = 2.3-4.5 months) versus 4.3 months (95% CI = 2.8-6.4 months; P = 0.003). In patients who had TKI discontinuation, dose reduction was associated with longer time on treatment in patients in the normal albumin group compared with patients in the hypoalbuminemia group or patients without dose reduction ( P < 0.0001). Patients in the hypoalbuminemia group experienced significantly more grade 3/4 adverse events compared with those in the normal albumin group (73% vs 27%, P < 0.0001). Conclusion and Relevance: Hypoalbuminemia is a risk factor for both shorter time on treatment and more severe adverse events in patients with solid tumor malignancies taking highly protein-bound oral TKIs. This study highlights the need for closer monitoring of this patient population by health care providers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, University of Chicago Medicine, Chicago, IL, USA.
- Department of Pharmacy, MultiCare Regional Cancer Center, Tacoma, WA, USA.
- Department of Pharmacy, University of Wisconsin Hospitals and Clinics, Madison, WI, USA.
ORCID-Profile: Sarvnaz Sadrameli
Zitieren
APA
Sadrameli, S., Bringgold, S., & Dow-Hillgartner, E. (2025). Tolerability Assessment of Tyrosine Kinase Inhibitors in Patients With Solid Tumor Malignancies and Hypoalbuminemia. Annals of Pharmacotherapy. https://doi.org/10.1177/10600280241284923
Vancouver
Sadrameli S, Bringgold S, Dow-Hillgartner E. Tolerability Assessment of Tyrosine Kinase Inhibitors in Patients With Solid Tumor Malignancies and Hypoalbuminemia. Annals of Pharmacotherapy. 2025. doi:10.1177/10600280241284923
BibTeX
@article{Sadrameli2025,
author = {Sadrameli, Sarvnaz and Bringgold, Sydney and Dow-Hillgartner, Elizabeth},
title = {Tolerability Assessment of Tyrosine Kinase Inhibitors in Patients With Solid Tumor Malignancies and Hypoalbuminemia},
journal = {Annals of Pharmacotherapy},
year = {2025},
doi = {10.1177/10600280241284923}
}
EUVIMED